11 – 20 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Growth and carbon sequestration by ectomycorrhizal fungi in intensively fertilized Norway spruce forests
(
- Contribution to journal › Article
- 2010
-
Mark
STROMA-DERIVED MARKERS PREDICTING BREAST CANCER PROGNOSIS AND TREATMENT RESPONSE
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.116-117(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
(
- Contribution to journal › Article
- 2006
-
Mark
Time dependent effects of tamoxifen treatment on cardiovascular morbidity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
(
- Contribution to journal › Published meeting abstract
-
Mark
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(
- Contribution to journal › Article
-
Mark
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(
- Contribution to journal › Article
- 2004
-
Mark
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer
(
- Contribution to journal › Article